SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm. Paxalisib phase II study in newly diagnosed glioblastoma has seen the final patient complete drug treatment; a number of patients remain in follow-up. EVT801 phase I study protocol has been submitted to the French regulatory agency for review. Kazia CEO, Dr James Garner , commented, "Kazia has seen an exceptionally busy first half, with excellent progress across our clinical programs. In particular, the GBM AGILE study is performing ahead of our forecasts in terms of recruitment. As we move into the second half of the year, we anticipate conclusion of the paxalisib phase II study, initial data readouts from a number of the paxalisib investigator-initiated studies in other forms of brain cancer, and commencement of the first-in-human phase I study of EVT801." GBM AGILE Almost twenty-five sites are currently open to the paxalisib arm in the United States .
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma15 Jun, 14:00, PR Newswire • Développer
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States,
Kazia''s investigational drug, Paxalisib, is set to be involved in its ninth ongoing clinical study. The post Heres why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today appeared first on The Motley Fool Australia .
Proactive news headlines including Okapi Resources, Global Energy Ventures, Kazia Therapeutics and QMines07 Jun, 06:17, GlobeNewswire • Développer
Sydney, June 07, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
The global effort to defeat cancer continues, with this ASX healthcare share commencing a new clinical study. The post Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today appeared first on The Motley Fool Australia .
Kazia Therapeutics Ltds (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system. The PI3K inhibitor class, to which paxalisib belongs, is well validated in lymphoma outside the brain; three of the four FDA-approved PI3K inhibitors are treatments for forms of lymphoma, but they are assumed ineffective for PCNSL since they cannot cross the blood-brain barrier. Leading cancer centre Dana-Farber Cancer Institute (DFCI) is a world-leading cancer treatment and research centre with its principal teaching affiliate being Harvard National Medical School. DFCI participates in as many as 600 clinical trials at any given time and has been an important contributor to the development of many important new cancer therapies. "Very sound rationale" Chief executive officer Dr James Garner said: We are delighted to see this study underway and congratulate Dr Nayak and her team on getting it launched. With paxalisib now in an international pivotal study for glioblastoma, we are increasingly focused on identifying other groups of patients who may benefit from the drug. There is a very sound rationale to explore PCNSL in this disease and we are looking forward to seeing the study progress. Strong research focus The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL, and is expected to recruit up to 25 patients, taking up to two years to complete.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia''s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner , will be presenting virtually at the upcoming LD Micro Invitational XI.
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the companys bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest. On May 31 executive director and CEO Dr James Garner purchased 10,000 shares in a direct interest, increasing the number of securities held to 430,000. Non-executive director Bryce Carmine acquired 20,000 shares on May 31 in a direct interest, increasing his holding to 372,692 shares. This follows multiple purchases made by KZA directors on May 3. March quarter highlights The company kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.
No summary available.
North European Oil Royalty Trust (NYSE:NRT) declared a quarterly dividend on Monday, May 3rd, Wall Street Journal reports. Shareholders of record on Friday, May 14th will be given a dividend of 0.14 per share by the energy company on Wednesday, May 26th. This represents a $0.56 annualized dividend and a dividend yield of 9.02%. The 
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
No summary available.